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ABSTRACT
Gastrointestinal stromal tumors (GISTs) are the most common non-epithelial tumors 
of the gastrointestinal tract. The most usual location is the stomach, followed by the 
small intestine, where it may cause digestive bleeding and anemia. Surgical resection 
of the tumor is the gold standard treatment, and definitive diagnosis is based on 
immunohistochemical analysis of the surgical specimen. We report the case of a 
53-year-old man with gastric GIST presenting with endophytic and exophytic growth, 
located at the posterior wall of the stomach, in the antrum-body transitional zone, 
treated with gastric sleeve.
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Gastrointestinal stromal tumors (GISTs) are the most common non-epithelial 
tumors of the gastrointestinal tract (GIT)1 and account for approximately 0.1-3% 
of all gastrointestinal tumors2. Its histological origin is related to the interstitial 
cells of Cajal, which act on the physiological control of peristaltic activity as 
an electric smooth muscle pacemaker. GISTs may affect any segment of the 
GIT, from the esophagus to the anus, where they have worse prognosis3. 
The sites of higher incidence are stomach (50-60%) and small intestine (25%), 
followed by colon and rectum (10%) and esophagus (< 5%)1,4. GISTs may 
also occur in the peritoneum, omentum and mesentery1,5. Most tumors are 
asymptomatic or present inconsequential symptoms such as abdominal pain 
(43%), upper gastrointestinal bleeding (15%) and palpable abdominal mass 
(17%), in addition to chronic anemia5,6. They occur most commonly in men and 
after 50 years of age5. Definitive diagnosis is based on immunohistochemical 
analysis of the surgical specimen, with search for the presence of CD117 
receptors (c-kit)7. The gold standard treatment is surgical resection of the 
tumor with negative margins (R0), with no need for lymphadenectomy as 
lymph node involvement is very rare1. In cases of malignant GIST, recurrence 
or when there is no possibility of resection, imatinib mesylate, a tyrosine 
kinase inhibitor, can be used as a treatment option8.
CASE REPORT
A 53-year-old Caucasian man, ex-smoker, presented with history of 
gout and complained of melena and anemia, requiring blood transfusion. 
Hemoglobin level was 8.7 mg/dL. Physical examination was normal. Upper 
digestive endoscopy demonstrated a lesion in the posterior gastric wall, in 
the antrum-body transitional zone, with a nodular formation of 5 cm adhered 
to deep structures, ulcerated and with recent signs of bleeding. An abdominal 
computed tomography (CT) scan identified a solid lesion in the gastric body 
compromising all the layers, measuring 6.4 × 4.2 × 4.1 cm (Figure 1). Based 
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on endoscopic and CT findings, the diagnostic 
suspicion was gastric GIST. The patient underwent 
videolaparoscopy, which detected a tumor in the 
posterior wall of the gastric antrum, next to the greater 
curvature, with endophytic and exophytic growth. 
The chosen approach was gastric sleeve surgery. 
Calibration of the gastric tube was maintained with 
Fouchet probe, and the lesion was treated with full 
resection with negative margins, which was confirmed by 
intraoperative frozen section examination. The resected 
surgical specimen (Figure 2) was removed from the 
abdominal cavity through a small magnification of 
the right hypochondrium, using a specimen retrieval 
bag. Pathology examination revealed an oval cell 
tumor measuring 6.3 × 4.5 cm and presence of three 
mitoses per 50 high-power field (HPF). No tumor 
necrosis or angiolymphatic and perineural invasion 
was identified, and the surgical limits were free of 
neoplasm. Metastasis was absent in seven resected 
perigastric lymph nodes. Tumor-free surgical margin 
measured 0.8 cm. Immunohistochemical study was 
performed using the indirect immunoperoxidase 
method with diaminobenzidine. Microscopically, 
neoplastic cells exhibited positive antibodies for 
DOG1, c-kit (CD117) and Ki-67 (5%). There were 
no positive antibodies for actina, desmina, CD34 
and S100. Therefore, the diagnosis of GIST with 
fusocellular and epithelioid pattern was reached, 
with proliferative index of 5%.
Figure 1: Upper digestive endoscopy and computed tomography scan showing a protruding, ulcerated lesion of the 
posterior wall of the gastric antrum.
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Figure 2: Resected lesion showing exophytic and endophytic 
growth.
DISCUSSION
GISTs may arise at any part of the GIT3 and at any 
age, with a higher incidence at 60 years. In addition, 
they affect men and women equally4,9. The main 
morphological parameters of differentiation of biological 
behavior related to malignancy and benignity are 
based on the size of the lesion and the number of 
mitoses per HPF5. Regarding immunohistochemical 
characteristics, CD117 protein, which is expressed 
in about 95% of GISTs, is helpful to differentiate 
them from other sarcomatous tumors of the GIT. 
On CD117-negative lesions, the marker DOG1 is useful 
for diagnosis as it is detected in approximately 97% of 
the cases. Other immunohistochemical markers such 
as SMA, S100 protein, PKC theta and desmin are 
also helpful5. The gold standard treatment is surgical 
resection of the tumor with negative margins (R0). 
Lymphadenectomy is not required because longitudinal 
submucosal spread with consequent lymph node 
involvement is very rare1. In some restricted cases, 
neoadjuvant administration of imatinib mesylate can 
be used to induce downstaging and, consequently, 
to improve rates of R0 resections, disease-free 
survival and overall survival when compared to 
upfront surgery. Furthermore, adjuvant therapy with 
imatinib mesylate is indicated for specific cases, 
such as tumor measuring more than 5 cm, more 
than 5 mitoses per 50 HPF, malignancy behavior, 
recurrence or when there is no possibility of resection10. 
With regard to the surgical technique, resection 
with a margin of 1-2 cm is usually recommended, 
although microscopic margins that are negative for 
tumor cells are sufficient for complete and curative 
resection11. During surgery, when removing the surgical 
specimen, caution should be taken in order not to 
cause tumor capsule rupture. In case of rupture, the 
disease progresses with peritoneal dissemination, 
given that there is a 100% chance of relapse, at least 
at the peritoneal level12. The surgical removal of the 
specimen must be done using a specimen retrieval 
bag in cases of videolaparoscopic approach, to avoid 
tumor capsule rupture inside the abdominal cavity. 
The surgical approach for the resection will depend on 
the tumor site. Typically, resections are easier in the 
stomach than in the duodenum due to the anatomic 
relationships with important structures1, for example. 
The prognosis of patients with GIST varies according 
to lesion location. Gastric lesions present the best 
prognosis, followed by small bowel, colorectal and 
extragastrointestinal GISTs13.
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